Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: Comparison of French-American-British and World Health Organization classifications

Journal of Hematology and Oncology

Volumn 9, Issue 1, 2016, Pages

  Pleyer, Lisa ^a,b,c   Burgstaller, Sonja ^d   Stauder, Reinhard ^e   Girschikofsky, Michael ^f   Sill, Heinz ^g   Schlick, Konstantin ^a,b,c   Thaler, Josef ^d   Halter, Britta ^e   Machherndl Spandl, Sigrid ^f   Zebisch, Armin ^g   Pichler, Angelika ^h   Pfeilstöcker, Michael ⁱ   Autzinger, Eva Maria ^j   Lang, Alois ^k   Geissler, Klaus ^l   Voskova, Daniela ^m   Geissler, Dietmar ⁿ   Sperr, Wolfgang R ^o   Hojas, Sabine ^o   Rogulj, Inga M ^p   Andel, Johannes ^h   Greil, Richard ^a,b,c   more..

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b Salzburg Cancer Research Institute   (Austria)

^c Cancer Cluster Salzburg   (Austria)

^d Klinikum Wels Grieskirchen GmbH   (Austria)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f ELISABETHINEN HOSPITAL   (Austria)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

^h LKH Leoben ^*  (Austria)

ⁱ HANUSCH HOSPITAL   (Austria)

^j WILHELMINEN HOSPITAL   (Austria)

^k Landeskrankenhaus Feldkirch   (Austria)

^l Hietzing Hospital   (Austria)

^m KEPLER UNIVERSITY HOSPITAL   (Austria)

ⁿ GENERAL HOSPITAL KLAGENFURT   (Austria)

^o MEDICAL UNIVERSITY OF VIENNA   (Austria)

^p University of Zagreb   (Croatia)

more..

Author keywords

AML; Austrian Azacitidine Registry; Azacitidine; Bone marrow blast count; Classification; FAB; MDS; RAEB t; WHO

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; CLOFARABINE; CYCLOSPORIN A; CYTARABINE; DECITABINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; LENALIDOMIDE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; THALIDOMIDE; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; AMERICAN; ANEMIA; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FRENCHMAN; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; REFERENCE VALUE; REFRACTORY ANEMIA WITH EXCESS BLASTS; SCORING SYSTEM; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; ACUTE DISEASE; AUSTRIA; CLASSIFICATION; COMPARATIVE STUDY; FRANCE; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OUTCOME ASSESSMENT; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGISTER; STATISTICS AND NUMERICAL DATA; UNITED KINGDOM; UNITED STATES; VERY ELDERLY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AUSTRIA; AZACITIDINE; FEMALE; FRANCE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; UNITED KINGDOM; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 84966373509     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-016-0263-4     Document Type: Article

References (81)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-99.
2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-49.
3. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Geneva, Switzerland: WHO Press; 2008.
4. Sanz GF, Sanz MA, Vallespí T, Cañizo MC, Torrabedella M, García S, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 1989;74:395-408.
5. De Rosa L, Montuoro A, Del Monte C. Myelodysplastic syndromes (MDS) with excess of blasts: identification of subgroups with different prognosis. Leuk Res. 1987;11:37.
6. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993;9:343-50.
7. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 1997;90:2969-77.
8. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-88.
9. Guerci AP, Feldmann L, Humbert JC, Guerci O. Refractory anemia with excess of blasts: a multivariate analysis of prognostic factors in 91 patients and a simplified scoring system for predicting survival. Eur J Haematol. 1995;54:241-4.
10. Michels SD, Saumur J, Arthur DC, Robinson LL, Brunning RD. Refractory anemia with excess of blasts in transformation hematologic and clinical study of 52 patients. Cancer. 1989;64:2340-6.
11. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia. 1993;7:1315-23.
12. Toyama K, Ohyashiki K, Yoshidam Y, Abe T, Asano S, Hirai H, et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia. 1993;7:499-508.
13. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419-25.
14. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: myelodysplastic syndromes guidelines, version 2.2015. 2015.
15. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223-32.
16. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res. 2000;24:983-92.
17. Germing U, Strupp C, Kuendgen A, Aivado M, Giagounidis A, Hildebrandt B, et al. Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals. Br J Haematol. 2006;132:162-7.
18. Breccia M, Latagliata R, Cannella L, Carmosino I, De Cuia R, Frustaci A, et al. Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal. Leuk Res. 2009;33:391-4.
19. Greenberg P, Anderson J, de Witte T, Estey E, Fenaux P, Gupta P, et al. Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol. 2000;18:3447-52.
20. Bennett JM. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol. 2000;72:131-3.
21. Head D. Problematic WHO, reclassification of myelodysplastic syndromes (response 2). J Clin Oncol. 2000;18:3447-52.
22. Breccia M, Latagliata R, Carmosino I, Gentilini F, D'Elia GM, Levi A, et al. Refractory anaemia with excess of blasts in transformation re-evaluated with the WHO criteria: identification of subgroups with different survival. Acta Haematol. 2007;117:221-5.
23. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895-903.
24. Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang J, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291-9.
25. Gavillet M, Noetzli J, Blum S, Duchosal MA, Spertini O, Lambert JF. Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine. Haematologica. 2012;97:1929-31.
26. Thepot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, et al. Azacitidine in untreated acute myeloid leukemia: a report on 149 patients. Am J Hematol. 2014;89:410-6.
27. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671-4.
28. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642-9.
29. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, et al. Is it time to redefine response in elderly patients with WHO-acute myeloid leukemia (AML) unfit for intensive chemotherapy? Blood. 2015;126:abstract 3742.
30. Schuh A, Dombret H, Sandhu I, Seymour JF, Stone RM, Al-Ali HK, Alimena G, Lewis I, Sang Kyun S, Geddes M, Cilloni D, Je-Hwan L, Songer S, Lucy LM, Beach C, Döhner H. Overall survival (OS) without complete remissions (CR) in older patients with acute myeloid leukemia (AML): azacitidine (AZA) vs conventional care regimens (CCR) in the AZA-AML-001 study. Haematologica. 2015;100(S1):219220.
31. Wattel E, de Botton S, Luc LJ, Preudhomme C, Lepelley P, Bauters F, et al. Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders. Br J Haematol. 1997;98:983-91.
32. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 1994;12:671-8.
33. Bernstein SH, Brunetto VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM, et al. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol. 1996;14:2486-94.
34. Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, et al. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013;13:592-6.
35. Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, O'Brien S, Fullmer A, et al. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013;13:131-8.
36. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562-9.
37. van der Helm LH, Veeger NJ, Kooy M, Beeker A, de Weerdt O, de Groot M, et al. Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30 % bone marrow blasts. Leuk Res. 2013;37:877-82.
38. Pollyea DA, Zehnder J, Coutre S, Gotlib JR, Gallegos L, Abdel-Wahab O, et al. Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica. 2013;98:591-6.
39. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97:1916-24.
40. Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2010;28:549-55.
41. Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007;109:5129-35.
42. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008;112:1638-45.
43. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114-24.
44. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, et al. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012;118:4471-7.
45. Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN, et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood. 2011;117:1828-33.
46. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, et al. Azacitidine in acute myeloid leukemia with >30 % bone marrow blasts and <15 G/L white blood cell count: results from the Austrian Azacitidine Registry of the AGMT study group versus randomized controlled phase III clinical trial data. Blood. 2015;126:abstract 2515.
47. Wang HI, Aas E, Howell D, Roman E, Patmore R, Jack A, et al. Long-term medical costs and life expectancy of acute myeloid leukemia: a probabilistic decision model. Value Health. 2014;17:205-14.
48. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670-7.
49. Miesner M, Haferlach C, Bacher U, Weiss T, Macijewski K, Kohlmann A, et al. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC). Blood. 2010;116:2742-51.
50. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367-76.
51. Gahn B, Haase D, Unterhalt M, Drescher M, Schoch C, Fonatsch C, et al. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia. 1996;10:946-51.
52. Gajewski JL, Ho WG, Nimer SD, Hirji KF, Gekelman L, Jacobs AD, et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol. 1989;7:1637-45.
53. Bertoli S, Bérard E, Huguet F, Huynh A, Tavitian S, Vergez F, et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood. 2013;121:2618-26.
54. de Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia. 1995;9:1805-11.
55. Montoro J, Coll R, Valcarcel D, Tormo M, Calbacho M, Bernal T, et al. IMPACT of therapeutic strategy and time to therapy initiation on clinical evolution in higher-risk myelodysplastic syndromes. A report from Erasme study. Blood. 2014;124:1908.
56. Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009;113:28-36.
57. Ostgard LS, Norgaard JM, Sengelov H, Holm MS, Jensen MK, Kallenbach M, et al. Impact of chemotherapy delay on short- and long-term survival in younger and older AML patients: a Danish population-based cohort study. Leukemia. 2014;28:1926-9.
58. Pelloso L, Rohr S, Yamamoto M, Chauffaille M. Time elapsed from AML diagnosis to induction chemotherapy affects overall survival. Journal of Cancer Therapy. 2013;4:957-960.
59. Wang JH, Guo Q, Ma ZX, Ma QL, Yu MX, Yin XF, et al. Impact of chemotherapy delay on overall survival for AML with IDH1/2 mutations: a study in adult Chinese patients. PLoS ONE. 2015;10:e0140622.
60. Hasserjian RP, Campigotto F, Klepeis V, Fu B, Wang SA, Bueso-Ramos C, et al. De novo acute myeloid leukemia with 20-29 % blasts is less aggressive than acute myeloid leukemia with >/=30 % blasts in older adults: a bone marrow pathology group study. Am J Hematol. 2014;89:E193-9.
61. Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, et al. Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J Hematol Oncol. 2013;6:32.
62. Pleyer L, Burgstaller S, Girschikofsky M, Linkesch W, Stauder R, Pfeilstocker M, et al. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann Hematol. 2014;93:1825-38.
63. Quintas-Cardama A, Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012;120:4840-5.
64. Ohyashiki K, Nishimaki J, Shoji N, Miyazawa K, Kimura Y, Ohyashiki JH. Re-evaluation of refractory anemia with excess blasts in transformation. Leuk Res. 2001;25:933-9.
65. Arber DA, Stein AS, Carter NH, Ikle D, Forman SJ, Slovak ML. Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol. 2003;119:672-80.
66. Estey E, Pierce S, Kantarjian H, O'Brien S, Beran M, Andreeff M, et al. Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leuk Lymphoma. 1993;11(S2):59-63.
67. Albitar M, Beran M, O'Brien S, Kantarjian H, Frieriech E, Keating M, et al. Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia. Blood. 2000;96:372-3.
68. Strupp C, Gattermann N, Giagounidis A, Aul C, Hildebrandt B, Haas R, et al. Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. Leuk Res. 2003;27:397-404.
69. Estey EH, Keating MJ, Dixon DO, Trujillo JM, McCredie KB, Freireich EJ. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia. Hematol Pathol. 1987;1:203-8.
70. Becker H, Suciu S, Ruter BH, Platzbecker U, Giagounidis A, Selleslag D, et al. Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). Ann Hematol. 2015;94:2003-13.
71. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454-65.
72. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Linkesch W, Pfeilstöcker M, et al. Azacitidine in patients with acute myeloid leukemia: assessing the potential negative impact of elevated baseline white blood cell count on outcome. Blood. 2014;124:abstract 3683.
73. Pleyer L, Germing U, Sperr WR, Linkesch W, Burgstaller S, Stauder R, et al. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leuk Res. 2014;38:475-83.
74. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Linkesch W, Pfeilstöcker M, Autzinger EM, Tinchon C, Sliwa T, Lang A, Sperr WR, Geissler D, Krippl P, Voskova D, Rossmann DH, Schlick K, Thaler J, Halter B, Machherndl-Spandl S, Theiler G, Valent P, Eckmüllner O, Greil R. Azacitidine in acute myeloid leukemia: comparison of patients with AML-MRF vs AML-NOS enrolled in the Austrian Azacitidine Registry. Blood. 2014;124(21):abstract 3681.
75. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Linkesch W, Pfeilstöcker M, Autzinger EM, Tinchon C, Sliwa T, Lang A, Sperr WR, Geissler D, Krippl P, Voskova D, Rossmann DH, Schlick K, Thaler J, Halter B, Machherndl-Spandl S, Theiler G, Valent P, Eckmüllner O, Greil R. Azacitidine in patients with acute myeloid leukemia: impact of intermediate-risk vs high-risk cytogenetics on patient outcomes. Blood. 2014;124(21):abstract 955.
76. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Linkesch W, Pfeilstöcker M, Autzinger EM, Tinchon C, Sliwa T, Lang A, Sperr WR, Geissler D, Krippl P, Voskova D, Rossmann DH, Schlick K, Thaler J, Halter B, Machherndl-Spandl S, Theiler G, Valent P, Eckmüllner O, Greil R. Azacitidine in patients with relapsed/refractory acute myeloid leukemia: retrospective analysis of the Austrian Azacitidine Registry. Blood. 2014;124(21):abstract 943.
77. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Linkesch W, Pfeilstöcker M, Autzinger EM, Tinchon C, Sliwa T, Lang A, Sperr WR, Geissler D, Krippl P, Voskova D, Rossmann DH, Schlick K, Thaler J, Halter B, Machherndl-Spandl S, Theiler G, Valent P, Eckmüllner O, Greil R. Azacitidine in patients with treatment-related acute myeloid leukemia: retrospective analysis of the Austrian Azacitidine Registry. Blood. 2014;124(21):abstract 2284.
78. Almeida A, Prebet T, Itzykson R, et al. Clinical outcomes of acute erythroleukemia treated with azacitidine: a retrospective multicenter study. Haematalogica. 2015;100(S1):absract E961.
79. Pleyer L, Stauder R, Thaler J, Ludwig H, Pfeilstocker M, Steinkirchner S, et al. Age- and comorbidity-specific evaluation of azacitidine treatment, response and overall survival in 184 patients in the Austrian Azacitidine Registry. Leuk Res. 2011;35:abstract 101.
80. Pleyer L, Stauder R, Thaler J, Ludwig H, Pfeilstöcker M, Steinkirchner T, et al. Overall survival data of patients with MDS, AML and CMML from the Austrian Azacitidine Registry of 184 consecutive patients. Leuk Res. 2011;35:abstract 100.
81. Doehner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453-74.